BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline ...
Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference ...
CervoMed Inc. announced that it will present topline results from its Phase 2b RewinD-LB study at the 8th International Lewy Body Dementia Conference in Amsterdam on January 31, 2025. The study ...
Please provide your email address to receive an email when new articles are posted on . In this video, James E. Galvin, MD, MPH, discusses the SHIMMER study, presented at the Alzheimer’s Association ...
CervoMed (CRVO) will deliver an oral presentation providing detailed safety and efficacy results from its completed RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies at ...
The details of the presentation will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/ following the presentation. About ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results